Arrowhead touts Phase Ib RNAi data for ccRCC; PureTech lines up PD-1 from BeiGene for upcoming combo study
Just days after getting walloped by the news that animal tox data forced them to halt an early-stage cystic fibrosis study, Arrowhead is touting some initial snapshots from their RNAi treatment for clear cell renal cell carcinoma.
Most of the positive signs they’re pointing to relate to biomarker activity, with an average 48% reduction in HIF2α protein among nine evaluable biopsy samples. Those reductions varied widely, though, starting at 9% and growing to 82%.
There was one partial tumor response in the small group, though researchers noted the patients had failed multiple lines of therapy. — John Carroll
PureTech lines up a PD-1 from BeiGene for upcoming combo study
PureTech has struck a supply deal with BeiGene to line up their PD-1 drug tislelizumab for a combination study involving LYT-200, an experimental antibody targeting galectin-9 for difficult-to-treat solid tumors.
This is part of a two-step effort to test PureTech’s drug as a monotherapy first, followed by the combination with tislelizumab and other agents.
“After a decade of optimizing use of immuno-oncology therapies, such as the checkpoint inhibitors that have certainly provided a paradigm shift in treating malignant diseases, we in the industry are eager to advance novel breakthrough agents and combinations to serve a wider range of cancer patients. Patients need new options as the first wave of immunotherapies work only in a small percentage of them. Well thought-out combination immunotherapy regimens may be that way forward,” said Aleksandra Filipovic, head of oncology at PureTech. — John Carroll
Biohaven reports better than expected sales on migraine drug, shares jump
Biohaven $BHVN saw its shares tick upward Wednesday morning after sharply beating sales estimates for its migraine drug Nurtec, following a recent new approval as a preventative.
Shares of the New Haven, CT-based biotech were trading higher by as much as 13% in early Wednesday trading after Nurtec reaped nearly $93 million in sales in the second quarter. Originally approved in February 2020 to treat acute migraines, Nurtec tacked on preventative treatment this past May.
“Our second quarter net revenue performance reflects the overwhelmingly positive feedback we are receiving from patients and healthcare providers about the impact of Nurtec ODT on migraine,” CCO BJ Jones said in a statement.
Biohaven says its oral CGRP drug covers about 95% of available migraine patients. It’s likely to face competition from AbbVie’s Ubrelvy, which launched just a couple of months before Nurtec in early 2020. — Max Gelman